OFFICE OF TECHNOLOGY COMMERCIALIZATION

PREVENTIVES & THERAPEUTICS

Intravenous Formulation of GMC1 for Cancer Treatment

SUMMARY

The University of Texas at El Paso seeks a partner for licensing a novel compound for the treatment of metastatic prostate cancer and other cancers and diseases that involve androgen, glucocorticoid and progesterone receptors.

TECHNOLOGY

The soluble formulation of GMC1 is suitable for intravenous and likely oral administration. GMC1 is a first in class drug for directly targeting the FKBP52 co-chaperone for the treatment of any condition that relies upon a functional androgen, progesterone or glucocorticoid signaling pathway.

ADVANTAGES

- Treats drug resistant metastatic cancer
- Strong drug safety profile
- Stable intravenous formulation
- Optimal water soluble co-solvent ratios
- Analysis method will enable further pre-clinical and clinical studies of GMC 1

APPLICATION

- Prostate cancer
- Breast cancer
- Benign prostatic hyperplasia
- Contraceptives
- Androgen receptor related disorders
- Glucocorticoid receptor related disorders
- Progesterone receptor related disorders



Figure: Structure of GMC1, a direct FKBP52 inhibitor.

INVENTORS

- Mark Cox
- Huan Xie
- Oscar Ekpenyong

PATENT STATUS

- Provisional Patent Filed

For more information, please contact Chao Zhang at UTEP's Office of Technology Commercialization.

Phone: (915) 747-6717 Email: czhang3@utep.edu Ref. #: 2016-023